The global market for RNA-Targeted Small Molecule Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key RNA-Targeted Small Molecule Drugs players cover Roche, Novartis, PTC Therapeutics, Biogen and Accent Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global RNA-Targeted Small Molecule Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global RNA-Targeted Small Molecule Drugs market, with both quantitative and qualitative data, to help readers understand how the RNA-Targeted Small Molecule Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the RNA-Targeted Small Molecule Drugs market and forecasts the market size by Type (mRNA Translation Regulation, RNA Splicing Modification and Direct RNA Targeting), by Application (SMA, Oncology, Lung Fibrosis and Huntington's Disease), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
Segmentation by application
Segmentation by region
Middle East & Africa
Major companies covered
Chapter 1: Scope of RNA-Targeted Small Molecule Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global RNA-Targeted Small Molecule Drugs market size and CAGR, RNA-Targeted Small Molecule Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: RNA-Targeted Small Molecule Drugs revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global RNA-Targeted Small Molecule Drugs revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global RNA-Targeted Small Molecule Drugs market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, etc.
Chapter 14: Research Findings and Conclusion